<DOC>
<DOCNO>
EP-0002262
</DOCNO>
<TEXT>
<DATE>
19790613
</DATE>
<IPC-CLASSIFICATIONS>
C07K-7/56 C07K-1/06 C07K-7/06 A61P-5/02 C07K-1/113 C07K-14/435 A61K-38/04 C07K-1/00 C07K-7/00 C07K-14/655 C07K-14/575 <main>C07C-103/52</main> A61K-37/02 A61P-5/00 A61K-38/00 
</IPC-CLASSIFICATIONS>
<TITLE>
somatostatin analogs and process for their preparation.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co. inc.<sep>merck &amp; co., inc.126, east lincoln avenue p.o. box 2000rahway new jersey 07065-0900us<sep>merck & co. inc.<sep>
</APPLICANT>
<INVENTOR>
veber daniel frank<sep>veber, daniel frank<sep>veber, daniel frank290 batleson roadus-19002 ambler, pennsylvaniaus<sep>veber, daniel frank<sep>veber, daniel frank290 batleson roadus-19002 ambler, pennsylvaniaus<sep>
</INVENTOR>
<ABSTRACT>
bicyclic somatostatin analogs and pharmaceutically  acceptable non-toxic acid addition salts thereof are prepared  by the solid phase method.  these analogs have the property  of inhibiting the release of insulin, glucagon and growth  hormone in humans and animals.  the compounds are  particularly useful in the treatment of diabetes.  due to the  bicyclic structure, these analogs are resistant to enzymatic  metabolism and have a longer duration of activity.  
</ABSTRACT>
</TEXT>
</DOC>
